Meningioma
Drug research and approvals for meningioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 64 studies of meningioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 64
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- IN10018 in Combination With Dalpiciclib for Progressive MeningiomasNCT07652762 · Phase 1 · Capital Medical University · starts Aug 31, 2026
- NK Cell Therapy for Malignant Solid Brain TumorsNCT07552233 · Not applicable · Peking University Third Hospital · starts Apr 1, 2026
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaNCT07533942 · Phase 2 · Jazz Pharmaceuticals · starts Jul 16, 2026
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During…NCT07493447 · Early Phase 1 · Eben Rosenthal · starts Jul 7, 2026
- A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616 · Phase 2 · Exelixis · starts May 21, 2026
- Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With MeningiomaNCT07418775 · Not reported · University of California, San Francisco · starts Jan 16, 2026
- Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus…NCT07413796 · Not applicable · Medical University of Warsaw · starts Feb 1, 2026
- Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsNCT07411690 · Not reported · Medical University of Warsaw · starts Feb 3, 2026
- Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive…NCT07398170 · Not applicable · University Hospital, Montpellier · starts Jul 13, 2026
Phase 3 3
- MifepristoneGlucocorticoid receptor antagonist
- Tranexamic acidPlasminogen inhibitor
- Aminolevulinic acidDNA inhibitor
Phase 2 12 of 22
- Lutetium oxodotreotideSomatostatin receptor binding agent
- EverolimusFK506-binding protein 1A inhibitor
- Gallium oxodotreotideDiagnostic agent
- Edotreotide
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- VismodegibSmoothened homolog inhibitor
- RegorafenibTyrosine-protein kinase ABL inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- PasireotideSomatostatin receptor 5 agonist
- OctreotideSomatostatin receptor agonist
Phase 1 or earlier 6
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- ErlotinibEpidermal growth factor receptor erbB1 inhibitor
- TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
- AlpelisibPI3-kinase p110-alpha subunit inhibitor
- AvelumabProgrammed cell death 1 ligand 1 other
- Dordaviprone
How its trials ended
195 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 27 whose ending is known, 15% met their primary endpoint, 7% missed it and 78% stopped early.
- Ongoing8242%
- Completed, result not reported6533%
- Status unknown2111%
- Stopped: other or unclear95%
- Stopped: enrollment or feasibility84%
- Met its primary endpoint42%
- Missed its primary endpoint21%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jun 29, 2026 | Ceritinib use for IGF1-receptor inhibition in meningioma – a phase 2 open- label study in recurrent grade 1 and 2 tumorsCeritinib | McGill University | Pending |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Nov 12, 2020 | 5-aminolevulinic acidDiagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma | NX Development Corp. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA